Internal Medicine, Hematology & Oncology · South Pasadena, CA
NPI
1609057157
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
209 Fair Oaks Ave
South Pasadena, CA, 91030
Phone (626) 396-2900
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.9M
128,386 services
Medicare patients, 2024
479
Average age 76
Drug cost, 2024
$3.7M
1,025 prescriptions
Company payments, 2025
$18.13
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Samuel W Chung Jr. was code J9263 (injection, oxaliplatin, 0.5 mg), 21,200 times for 15 patients. In total Samuel W Chung Jr. billed 128,386 services in 110 codes, and Medicare paid $2.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-12-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 21,200 | 15 | $0.06 | $1,189 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 16,400 | 17 | $44.50 | $730K |
| J0185 Injection, aprepitant, 1 mg | Office | 12,610 | 23 | $1.35 | $17K |
| J9267 Injection, paclitaxel, 1 mg | Office | 6,279 | 12 | $0.08 | $512 |
| J0897 Injection, denosumab, 1 mg | Office | 4,500 | 45 | $20.37 | $92K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,876 | 30 | $0.07 | $138 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,402 | 30 | $0.09 | $127 |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 915 | 13 | $3.54 | $3,243 |
| 99214 Office E&M - Established | Office | 803 | 200 | $107.87 | $87K |
| J9190 Injection, fluorouracil, 500 mg | Office | 602 | 13 | $2.31 | $1,389 |
| 96375 Injection Administration | Office | 426 | 50 | $14.13 | $6,019 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 394 | 171 | $14.22 | $5,604 |
| 96413 Chemotherapy Administration | Office | 338 | 74 | $122.02 | $41K |
| J9045 Injection, carboplatin, 50 mg | Office | 265 | 16 | $2.80 | $743 |
| 99233 Hospital E&M - Subsequent | Facility | 251 | 76 | $100.72 | $25K |
By year: 2022 $2.5M for 116,524 services; 2023 $2.5M for 139,832 services; 2024 $2.9M for 128,386 services.
Medicare prescription drug claims, 2024
In 2024, the drug Samuel W Chung Jr. prescribed most often to Medicare patients was Xtandi (Enzalutamide), with 85 prescriptions and refills. In total Samuel W Chung Jr. wrote 1,025 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xtandi Enzalutamide | 85 | 85 | Under 11 | $1.1M |
| Anastrozole Generic | 60 | 122 | 14 | $912 |
| Prochlorperazine Maleate Generic | 47 | 47 | 35 | $656 |
| Prednisone Generic | 37 | 40 | Under 11 | $335 |
| Ondansetron Hcl Generic | 35 | 35 | 25 | $746 |
| Dexamethasone Generic | 35 | 37 | 25 | $607 |
| Tagrisso Osimertinib Mesylate | 31 | 31 | Under 11 | $612K |
| Hydroxyurea Generic | 30 | 46 | Under 11 | $242 |
| Abiraterone Acetate Generic | 28 | 32 | Under 11 | $203K |
| Gabapentin Generic | 28 | 28 | Under 11 | $309 |
| Morphine Sulfate Er Morphine Sulfate | 28 | 28 | Under 11 | $1,115 |
| Alendronate Sodium Generic | 24 | 62 | Under 11 | $180 |
| Famotidine Generic | 22 | 28 | 16 | $79.37 |
| Everolimus Generic | 22 | 22 | Under 11 | $188K |
| Eliquis Apixaban | 22 | 32 | Under 11 | $17K |
Brand drugs: 267 claims; generic drugs: 758 claims; opioid claims: 77.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Samuel W Chung Jr. $18.13 ($18.13 in general payments such as food, travel and fees) from 1 company. The largest payer was Puma Biotechnology, Inc. with $18.13.
| Company | Payments | Amount |
|---|---|---|
| Puma Biotechnology, Inc. PBYI | 1 | $18.13 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.